Research & Innovation

Leukemia Clinical Trials

Clinical Trials

BeiGene BGB-3111-215

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib

Physician & Study Coordinator

Physician

Subhash Proothi, MD

Subhash Proothi, MD

Study Coordinator

Lauren Downing, BS, CCRP
484-526-7936

lauren.downing@sluhn.org

 

 

Close

Synopsis

Treatment Agent: Zanubrutinib

Synopsis: You are being asked to take part in this study because you have been diagnosed with a cancer called Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

The purpose of this study is to study the safety and efficacy of the study drug zanubrutinib (also known as BGB-3111) in Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) patients who discontinued prior ibrutinib treatment due to toxicities. 

Zanubrutinib is an experimental drug. This means that it has not been approved for use by the regulatory agencies in any country, but it can be used in research studies such as this one. As of September 2018, zanubrutinib has been given to approximately 1200 participants who are taking or have taken part in research studies with zanubrutinib as a single drug or in combination with another anticancer drug.

Zanubrutinib blocks a protein called Bruton Tyrosine Kinase (BTK). BTK helps CLL/SLL cells live and grow. By blocking BTK, zanubrutinib is capable of stopping or slowing down the growth and activity of CLL/SLL cells, which can lead to improvement in the symptoms associated with CLL/SLL. However, not all patients will improve to the same degree, and some patients might not improve at all.

Close

Inclusion Criteria
  • Age 18 years or older receiving treatment with ibrutinib for a minimum of 4 weeks prior to enrollment
  • CLL or SLL that meets diagnostic criteria and requires treatment by 2008 iwCLL criteria prior to initiation of ibrutinib.
  • Intolerant to ibrutinib
  • Ibrutinib-related toxicities must have resolve to Grade ≤ 1 or baseline prior to initiating treatment with zanubrutinib
  • ECOG performance status ≤ 2
  • Adequate bone marrow function
  • Adequate renal and hepatic function
  • Close

    Exclusion Criteria
    1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
    2. Intervening anticancer therapy after discontinuation of ibrutinib and prior to initiation of zanubrutinib
    3. Clinically significant cardiovascular disease
    4. History of ischemic stroke within 180 days before first dose of zanubrutinib
    5. History of CNS hemorrhage
    6. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast
    7. History of inherited or acquired hemorrhagic coagulopathy
    8. Unable to swallow capsules, or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
    9. Active fungal, bacterial, and/or viral infection requiring systemic therapy
    10. Known CNS involvement by leukemia or lymphoma
    11. Documented progressive disease (PD) during ibrutinib treatment up to the time of enrollment
    12. Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs
    13. Known infection with HIV or active viral hepatitis B or C infection
    14. History of opportunistic infection while on ibrutinib
    15. Major surgery within 4 weeks of the first dose of study drug
    16. Pregnant or lactating women
    17. Ongoing alcohol or drug addiction
    18. Prior exposure to zanubrutinib or hypersensitivity to zanubrutinib formulation excipients
    19. Concurrent participation in another therapeutic clinical trial

    Close

    Millennium Pevonedistat-3001

    A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

    Physician & Study Coordinator

    Physician

    Yacoub Faroun, MD

    Yacoub Faroun, MD

    Study Coordinator

    Lauren Downing, BS, CCRP
    484-526-7936

    Lauren.Downing@sluhn.org

     

     

    Close

    Synopsis

    Treatment Agent: Pevonedistat

    Synopsis: The purpose of this research study is to evaluate pevonedistat in combination with azacitidine in patients with higher-risk MDS, CMML, and low-blast AML. If you choose to participate in this study, you will be treated with azacitidine. Azacitidine is a widely used treatment for patients with these diseases. In addition, you may also be treated with the investigational drug pevonedistat. An investigational drug means that the FDA (U.S. Food and Drug Administration) and other regulatory authorities have not approved the drug. Pevonedistat is currently being studied in humans with advanced solid tumors, higher-risk MDS, CMML, and acute myelogenous leukemia (AML). This study will assess whether taking pevonedistat in combination with azacitidine increases the amount of time you live without any worsening of your disease when compared to azacitidine alone.

    Close

    Inclusion Criteria
    • Has morphologically confirmed diagnosis of myelodysplastic syndromes (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) (i.e., with white blood cell [WBC] <13,000/μL) or low-blast acute myelogenous leukemia (AML).
    • Has MDS or CMML and must also have one of the following Prognostic Risk Categories, based on the Revised International Prognostic Scoring System (IPSS-R):
      • Very high (>6 points).
      • High (>4.5-6 points).
      • Intermediate (>3-4.5 points): a patient determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of >=5% bone marrow myeloblasts.
    • Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2.
    • Participants with AML (20%-30% blasts) must have a treatment-related mortality (TRM) score >=4 for intensive, induction chemotherapy as calculated using the simplified model described by Walter and coworkers.
    • Calculation of TRM score:
      • 0 for (age <61 years), +2 for (age 61-70 years), +4 for (age >71 years).
      • + 0 for (PS=0), +2 for (PS=1), +4 for (PS >1).
      • + 0 for (platelets <50), +1 for (platelets >50).

    Close

    Exclusion Criteria
    • Has previous treatment for higher-risk myelodysplastic syndromes (HR MDS) or low-blast AML with chemotherapy or other antineoplastic agents including hypomethylating agent (HMAs) such as decitabine or azacitidine. Previous treatment is permitted with hydroxyurea and with lenalidomide, except that lenalidomide may not be given within 8 weeks before the first dose of study drug.
    • Has acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
    • Is eligible for intensive chemotherapy and/or allogeneic stem cell transplantation. The reason a participant is not eligible for intensive chemotherapy and/or allogeneic stem cell transplantation may consist of one or more of the following factors:
      • Age >75.
      • Comorbidities.
      • Inability to tolerate intensive chemotherapy (e.g., patients with AML with 20%-30% blasts and TRM ≥4).
      • Physician decision (e.g., lack of available stem cell donor).
      • The reason a participant is not eligible should be documented in the electronic case report form (eCRF).
    • Has either clinical evidence of or history of central nervous system involvement by AML.
    • Has active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
    • Is diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease.
    • Has nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.
    • Has prothrombin time (PT) or aPTT >1.5× upper limit of normal (ULN) or active uncontrolled coagulopathy or bleeding disorder. Participants therapeutically anticoagulated with warfarin, direct thrombin inhibitors, direct factor Xa inhibitors, or heparin are excluded from enrollment.
    • Has known human immunodeficiency virus (HIV) seropositive.
    • Has known hepatitis B surface antigen seropositive, or known or suspected active hepatitis C infection. Note: Participants who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load.
    • Has known hepatic cirrhosis or severe preexisting hepatic impairment.
    • Has known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), and/or myocardial infarction within 6 months before first dose, or severe pulmonary hypertension.
    • Has treatment with strong cytochrome P 3A (CYP3A) inducers within 14 days before the first dose of pevonedistat.

    Close